GPC
JAZZ icon

Glacier Peak Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Glacier Peak Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-7,500
Closed -$1.07M – 79
2019
Q1 		$1.07M Buy
+7,500
New +$978K 0.98% 37

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Glacier Peak Capital's JAZZ Position: Q2 2019 in Review

Glacier Peak Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2019, closing a stake of 7,500 shares — an estimated $1.07M sold.

Glacier Peak Capital first reported a position in JAZZ in Q1 2019 and held it in 1 quarter. The position peaked at $1.07M in Q1 2019. 416 funds tracked by Wall St. Rank hold JAZZ as of Q2 2019.

  • Glacier Peak Capital reported no remaining Jazz Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Glacier Peak Capital sold 7,500 Jazz Pharmaceuticals shares in Q2 2019, an estimated $1.07M.
  • Glacier Peak Capital first reported a position in Jazz Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Glacier Peak Capital's Jazz Pharmaceuticals position peaked at $1.07M in Q1 2019.
  • 416 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2019.

Based on Glacier Peak Capital's 13F filing for Q2 2019, filed 12 Aug 2019.